At the time of writing, Black Diamond Therapeutics Inc [BDTX] stock is trading at $5.36, up 14.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BDTX shares have gain 7.09% over the last week, with a monthly amount drifted -10.96%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Black Diamond Therapeutics Inc [NASDAQ: BDTX] stock has seen the most recent analyst activity on July 31, 2024, when Raymond James initiated its Outperform rating and assigned the stock a price target of $20. On June 30, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $11 on June 28, 2023. Wedbush upgraded its rating to a Outperform but $10 remained the price target by the analyst firm on June 27, 2023. Wedbush downgraded its rating to Neutral for this stock on March 29, 2022. In a note dated March 22, 2022, H.C. Wainwright downgraded an Neutral rating on this stock.
For the past year, the stock price of Black Diamond Therapeutics Inc fluctuated between $1.62 and $7.66. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $5.36 at the most recent close of the market. An investor can expect a potential return of 175.19% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -17.83%, Pretax Profit Margin comes in at -16.46%, and Net Profit Margin reading is -16.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.69 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.94 points at the first support level, and at 4.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.57, and for the 2nd resistance point, it is at 5.79.
Ratios To Look Out For
It is important to note that Black Diamond Therapeutics Inc [NASDAQ:BDTX] has a current ratio of 6.87. As well, the Quick Ratio is 6.87, while the Cash Ratio is 1.78.
Transactions by insiders
Recent insider trading involved David Epstein, Former Employer, that happened on Jul 31 ’24 when 50000.0 shares were purchased. Former Employee, David Epstein completed a deal on Jul 26 ’24 to buy 50000.0 shares. Meanwhile, 10% Owner BIOTECH GROWTH N V bought 0.4 million shares on Oct 17 ’23.
